BUZZ-Creative Medical rises on FDA's 'orphan drug' tag for transplantation therapy

Reuters03-06

** Shares of biotech firm Creative Medical Technology Holdings rise 35% to $5.58 premarket

** Co says the U.S. Food and Drug Administration (FDA) has granted "orphan drug" status to its experimental immunotherapy to prevent graft rejection in patients with brittle type 1 diabetes, undergoing pancreatic islet cell transplantation

** Brittle type 1 diabetes is characterized by extreme fluctuations in blood glucose levels

** In islet cell transplantation, insulin-producing cells in the pancreas (islets) are transplanted from a donor into a person with type 1 diabetes

** The therapy, CELZ-101, uses the patient's own regulatory T cells to combat immune responses that can destroy islets - CELZ

** Orphan drug status is given by the FDA to drugs that treat rare conditions and are protected through a series of government incentives once in market

** Up to last close, stock was down 35.5% in the last 12 months

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment